MeSH D011349 - proctitis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Mesalamine | Mesalamine | 2019-05-09 | |||
| Padagis | Mesalamine | Mesalamine | 2004-09-17 | |||
| Mylan | Mesalamine | Mesalamine | 2018-11-20 | |||
| Mesalamine | Sfrowasa | 2027-07-24 | 1987-12-24 | |||
| Quagen Pharma | Mesalamine | Mesalamine | 2015-11-24 | |||
| Sandoz | Mesalamine | Mesalamine | 2019-06-12 | |||
| Allergan | Mesalamine | Asacol | 1992-01-31 | $88.1 M | Q2/19-Q1/20 | |
| Mesalamine | Mesalamine | 2018-03-23 | ||||
| Takeda | Mesalamine | Lialda | 2007-01-16 | |||
| Mesalamine | Pentasa | 1993-05-10 | ||||
| Zydus Therapeutics | Mesalamine | Mesalamine | 2017-06-05 | |||
| Sun Pharmaceutical Industries | Mesalamine | Mesalamine | 2019-01-25 | |||
| Alembic Pharmaceuticals | Mesalamine | Mesalamine | 2022-10-28 |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
100%2/2
Phase 3
67%2/3
Approved: 1Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use